These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21680815)

  • 1. Making translation work.
    Williams RS; Desmond-Hellmann S
    Science; 2011 Jun; 332(6036):1359. PubMed ID: 21680815
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of public-sector research in the discovery of drugs and vaccines.
    Stevens AJ; Jensen JJ; Wyller K; Kilgore PC; Chatterjee S; Rohrbaugh ML
    N Engl J Med; 2011 Feb; 364(6):535-41. PubMed ID: 21306239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-engineering drug discovery and development.
    FitzGerald GA
    LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An audience with...Francis Collins. Interviewed by Asher Mullard.
    Collins F
    Nat Rev Drug Discov; 2011 Jan; 10(1):14. PubMed ID: 21151031
    [No Abstract]   [Full Text] [Related]  

  • 5. Science and the law. Working through the patent problem.
    Walsh JP; Cohen WM; Arora A
    Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 7. Intellectual property rights. Public sector collaboration for agricultural IP management.
    Atkinson RC; Beachy RN; Conway G; Cordova FA; Fox MA; Holbrook KA; Klessig DF; McCormick RL; McPherson PM; Rawlings HR; Rapson R; Vanderhoef LN; Wiley JD; Young CE
    Science; 2003 Jul; 301(5630):174-5. PubMed ID: 12855794
    [No Abstract]   [Full Text] [Related]  

  • 8. Reinventing bioinnovation.
    Kaitin KI; Honig PK
    Clin Pharmacol Ther; 2013 Sep; 94(3):279-83. PubMed ID: 23963211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Universities shun Europe's drug initiative.
    Gilbert N
    Nature; 2010 Jul; 466(7304):306-7. PubMed ID: 20631770
    [No Abstract]   [Full Text] [Related]  

  • 10. Catalyzing the Critical Path Initiative: FDA's progress in drug development activities.
    Parekh A; Buckman-Garner S; McCune S; ONeill R; Geanacopoulos M; Amur S; Clingman C; Barratt R; Rocca M; Hills I; Woodcock J
    Clin Pharmacol Ther; 2015 Mar; 97(3):221-33. PubMed ID: 25670629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA launches priority vouchers for neglected-disease drugs.
    Waltz E
    Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
    [No Abstract]   [Full Text] [Related]  

  • 12. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 13. Rising costs hold up drug discovery.
    Miller HI
    Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
    [No Abstract]   [Full Text] [Related]  

  • 14. Is pharma running out of brainy ideas?
    Miller G
    Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165
    [No Abstract]   [Full Text] [Related]  

  • 15. The art of the alliance.
    Menzel GE; Xanthopoulos KG
    Nat Biotechnol; 2012 Apr; 30(4):313-5. PubMed ID: 22491275
    [No Abstract]   [Full Text] [Related]  

  • 16. Role and reality: technology transfer at Canadian universities.
    Bubela TM; Caulfield T
    Trends Biotechnol; 2010 Sep; 28(9):447-51. PubMed ID: 20598388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery.
    Rai AK; Reichman JH; Uhlir PF; Crossman C
    Yale J Health Policy Law Ethics; 2008; 8(1):1-36. PubMed ID: 18564492
    [No Abstract]   [Full Text] [Related]  

  • 18. Is the drought over for pharming?
    Kaiser J
    Science; 2008 Apr; 320(5875):473-5. PubMed ID: 18436771
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug development for neglected diseases - the trouble with FDA review vouchers.
    Kesselheim AS
    N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
    [No Abstract]   [Full Text] [Related]  

  • 20. Biotechnology and patent term extension issues.
    Raines L
    Food Drug Law J; 1999; 54(2):237-40. PubMed ID: 11758579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.